

GENOMIC VALLEY BIOTECH LIMITED

[GIN : L01122HR1994PLC033029]

4 KM Stone, Beri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



Date: 12th November, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Submission of Outcomes of Board Meeting and Un-Audited Financial Results for the quarter ended 30.09.2022 and year to date from 01.04.2022 to 30.09. 2022

1. Intimation and disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Un-Audited Financial Results and Limited Review Report for the quarter ended 30.09.2022 and year to date from 01.04.2022 to 30.09. 2022

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ("Company") in its meeting held today approved the Un-Audited Financial Results (Standalone) of the Company for the Quarter ended 30.09.2022 and year to date from 01.04.2022 to 30.09.2022 as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal.

The above information will also be available on the Company's Website, www.genomicvalley.com.

The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 01:10 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Yogesh Agrawal
Managing Director
DIN: 01165288
Add: G-74, Pushkar Enclave,
Paschim Vihar Delhi – 110063

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Genomic Valley Biotech Limited today reported its financial performance for the quarter ended on 30th September, 2022 and
Year to date from 01st April, 2022 to 30th September, 2022

In Rs.

Sr. No.	Particular	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for corresponding period ended	Previous year ended
		30-Sep-22	30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21	31-Mar-22
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Revenue From Operations	205,000	10,338,000	289,800	10,543,000	459,400	705,640
II	Other Income	80,000	144,877	-	224,877	-	840,070
III	Total Revenue (I+II)	285,000	10,482,877	289,800	10,767,877	459,400	1,545,710
IV	Expenses						
	Cost of materials consumed	0	-	4000	-	4,000	19,410
	Purchases of Stock-in-Trade	-	9,817,600	-	9,817,600	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-	-
	Employee benefits expense	151,610	825,487	246,250	977,097	423,450	1,398,781
	Financial costs	-	-	-	-	426,203	426,203
	Depreciation and amortization expense	76,324	76,324	470,238	152,648	940,476	840,873
	Other expenses	367,420	275,549	140,967	642,969	324,681	3,068,718
	Total Expenses (IV)	595,354	10,994,960	861,455	11,590,314	2,118,810	5,753,985
V	Profit / (Loss) before exceptional item and tax (III-IV)	-310,354	-512,083	-571,655	-822,437	-1,659,410	-4,208,275
VI	Exceptional Item	925,000	5,104,788	-	6,029,788	-	4,191,783
VII	Profit/loss before Tax (V-VI)	614,646	4,592,705	-571,655	5,207,351	-1,659,410	-16,492
VIII	Tax expenses						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	76,910
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	614,646	4,592,705	-571,655	5,207,351	-1,659,410	-93,402
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	614,646	4,592,705	-571,655	5,207,351	-1,659,410	-93,402
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	614,646	4,592,705	-571,655	5,207,351	-1,659,410	-93,402
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
XVII	Earning Per Equity Share (for continuing operation):						
	1) Basic	0.20	1.50	-0.19	1.70	-0.54	-0.03
	2) Diluted	0.20	1.50	-0.19	1.70	-0.54	-0.03
XVIII	Earning Per Equity Share (for discontinued operation):						
	1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):						
	1) Basic	0.20	1.50	-0.19	1.70	-0.54	-0.03
	2) Diluted	0.20	1.50	-0.19	1.70	-0.54	-0.03

Kamran



GENOMIC VALLEY BIOTECH LIMITED


REGD. OFF: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30 SEPTEMBER, 2022

Particulars	Amount in INR		
	30.09.2022	30.09.2021	31.03.2022
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit As Statement Profit & Loss	-822,437	-1,659,410	-4,208,275
Adjustment For			-
Discount received	-	-	-
Non-Operating Income	-	-	-
Interest Income	224,877	-	784,598
Gain/(Loss) on sale of assets	-6,029,788	-	-4,191,783
Depreciation and Amortisation Expenses	152,648	940,476	840,873
Operating Profit Before Change in Working Capital	-6,474,700	-718,934	-6,774,587
ADJUSTMENTS FOR WORKING CAPITAL:			
Increase/Decrease in Loans and Advances	-3,202,389	-	1,950,000
Increase/ Decrease in Inventories	-	-	-
Increase/Decrease in Security Deposits	-	-16,000,000	-
Increase/Decrease in Trade Receivables	-12,583,900	-65,880	649,119
Increase/Decrease in Other Current Assets	9,425,335	-439,186	-10,474,389
Increase/Decrease in Current Liabilities	-2,358,209	-5,433,218	-6,645,124
CASH GENERATED FROM OPERATIONS	-15,193,863	-22,657,216	-21,294,982
Taxes Paid			
Total (A)	-15,193,863	-22,657,216	-21,294,982
B. CASH FLOW FROM INVESTING ACTIVITIES			
Additions/Sales to fixed assets	15,504,788	49,166,000	53,462,783
Purchase/Sell of Investments	-	-	-
Discount received	-	-	-
Non-Operating Income	-	-	-16,000,000
Interest Income	-224,877	-	-784,598
Total (B)	15,279,911	49,166,000	36,678,185
C. CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from Borrowings		-26,545,944	-15,470,944
Preliminary Expenses	-	-	-
Total (C)	-	-26,545,944	-15,470,944
NET CASH FLOWS DURING THE YEAR (A+B+C)	86,048	-37,161	-87,741
Cash and Cash Equivalents (Opening Balance)	26,791	114,532	114,532
Cash and Cash Equivalents (Closing Balance)	112,839	77,371	26,791

[Handwritten Signature]




Statement of Asset and Liabilities as at 30.09.2022

Particulars	Current half year ended	Previous year ended
	30/09/2022	31/03/2022
	Un-Audited	Audited
	Standalone	Standalone
ASSETS		
Non Current Assets		
Property, plant and equipment	13,948,628	17,546,488
Capital work in progress	-	-
Other Intangible assets	-	-
Intangible assets under development	-	-
Financial assets	-	-
Investment	-	-
Loans	12,202,389	9,000,000
Security Deposits	50,000	50,000
Other financial assets	-	-
Deferred tax assets (Net)	3,902	3,902
Other non current assets	-	-
Total Non-Current Assets	26,204,919	26,600,390
Current Assets		
Inventories	-	-
Financial Assets:	-	-
Investments	-	-
Trade Receivables	12,583,900	-
Cash and Cash equivalents	61,560	-
Other Balances with banks	51,279	26,791
Loans	-	-
Other financial assets	-	-
Other Current assets	1,921,708	11,347,043
Total Current Assets	14,618,447	11,373,835
Total Assets	40,823,366	37,974,225
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	30,545,000	30,545,000
Othe Equity	3,448,594	-1,758,757
Total Equity	33,993,594	28,786,243
Non Current Liabilities		
Financial liabilities		
Borrowings	-	-
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	-	-
Provisions	-	-
Other Non Current liabilities	6,085,000	7,045,000
Total Non Current Liabilities	6,085,000	7,045,000
Current Liabilities		
Financial liabilities		
Borrowings	-	-
Trade Payables	31,860	-
Other Financials liabilities	-	-
Provisions	-	145,426
Other Current liabilities	712,913	1,997,556
Total Current Liabilities	744,773	2,142,982
TOTAL EQUITY AND LIABILITIES	40,823,366	37,974,225

Notes :


- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on November 12, 2022. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.

K. G. Singh



- 2 The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Comapnies Act, 2013 and other accounting principles generally accepted in India.
- 3 Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- 4 Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited



A handwritten signature in black ink, appearing to read "Yogesh Agrawal".

Yogesh Agrawal
(Chairman & Managing Director)
DIN-01165288

Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063

Place : Delhi
Dated : 12/11/2022

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email: cabhavukgarg@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter ended on
September 30, 2022 and year to date from April 01, 2022 to September 30, 2022**

We have reviewed the accompanying statement of unaudited financial results for the Quarter ended on September 30, 2022 and year to date from April 01, 2022 to September 30, 2022 ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.


This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement has been prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ANDROS & CO.
Chartered Accountants



Bhavuk Garg
2

(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

Place: Delhi
Date: 12-11-2022

UDIN: 22502310-BCXJGB-6501
Peer Review: a2121